Genmab Discloses Orbis as New 5% Major Shareholder

End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Genmab ( (GMAB) ) is now available. Genmab A/S reported on April 1, 2026, that Orbis Investment Management Limited had become a major shareholder as of March 31, 2026, holding 3,221,620 shares, equivalent to 5.01% of Genmab’s share capital and voting rights. The disclosure, made under Denmark’s capital markets rules, underscores growing institutional interest in the biotech group and may signal increased investor confidence in Genmab’s antibody-focused pipeline and long-term growth prospects. The major shareholder notification formalizes Orbis’s stake, giving the fund a meaningful voice in shareholder decisions at a time when Genmab continues to advance late-stage clinical programs. While the filing itself does not alter day-to-day operations, the enlarged institutional backing could influence future governance dynamics and market perception of the company’s strategic direction. The most recent analyst rating on (GMAB) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page. Spark’s Take on GMAB Stock According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral. The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings. To see Spark’s full report on GMAB stock, click here. More about Genmab Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines to treat cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates and immune-modulating antibodies, powering eight approved medicines and a late-stage clinical pipeline. Average Trading Volume: 1,763,501 Technical Sentiment Signal: Sell Current Market Cap: $16.34B Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.